Merck posts Q3 beat, lifts 2026 profit outlook on strong Keytruda sales

Merck reported third‑quarter 2026 revenue of $18.1 billion, up about 5 % year‑over‑year, and adjusted earnings of $2.49 per share, surpassing consensus. The company raised its full‑year 2026 adjusted EPS guidance to $2.77‑$2.82 and narrowed revenue guidance to $66.8‑$67.3 billion, citing robust Keytruda and Keytruda Qlex sales. Both GAAP and non‑GAAP EPS include a one‑time $0.12 per‑share expense tied to a global licensing deal with SciBrunch Therapeutics.

The higher guidance expands the earnings outlook for shareholders, while the one‑time $0.12 per‑share charge is reflected in both GAAP and non‑GAAP results, meaning future quarters will not carry this expense. Analysts such as Jefferies lifted their price target to $177, indicating expectations of continued earnings growth.

  • 1Q3 2026 revenue was $18.1 billion, a 5 % increase versus the prior year.
  • 2Adjusted EPS for Q3 2026 was $2.49 per share.
  • 3GAAP EPS for Q3 2026 was $2.04 per share.
  • 4Keytruda and Keytruda Qlex together generated $8.6 billion in sales, with Qlex contributing $830 million.
  • 5Adjusted 2026 EPS guidance was raised to $2.77‑$2.82 per share.
  • 62026 revenue guidance was narrowed to $66.8‑$67.3 billion.

Sources